PMID- 24011538
OWN - NLM
STAT- MEDLINE
DCOM- 20140514
LR  - 20220311
IS  - 1879-0852 (Electronic)
IS  - 0959-8049 (Linking)
VI  - 50
IP  - 1
DP  - 2014 Jan
TI  - A systematic review of cost-effectiveness of monoclonal antibodies for metastatic 
      colorectal cancer.
PG  - 40-9
LID - S0959-8049(13)00772-7 [pii]
LID - 10.1016/j.ejca.2013.08.008 [doi]
AB  - Metastatic colorectal cancer (mCRC) imposes a substantial health burden on 
      patients and society. In recent years, advances in the treatment of mCRC have 
      mainly resulted from the introduction of monoclonal antibodies (MoAbs). However, 
      the application of these MoAbs considerably increases treatment costs. The 
      objective of this article is to review and assess the economic evidence of MoAB 
      treatment in mCRC. A systematic literature review was conducted and 
      cost-effectiveness (CE) as well as cost-utility-studies were identified. For 
      this, Medline, Embase, SciSearch, Cochrane, and nine other databases were 
      searched from 2000 through February 2013 for full-text publications. The quality 
      of the studies was assessed via a validated assessment tool (Quality of Health 
      Economic Studies (QHES)). A total of 843 publications were screened. Of those, 15 
      studies involving the MoAbs bevacizumab, cetuximab and panitumumab met all 
      inclusion criteria. Four studies analysed the CE of first-line treatment with 
      bevacizumab and nine the CE of cetuximab in subsequent treatment lines. Two 
      studies dealt with the CE of panitumumab. The analysis of sequential regimes and 
      the direct comparison of two MoABs were analysed by only one study each. The 
      quality of the included studies was high with the exception of one study. 
      CONCLUSIONS: The treatment with bevacizumab, cetuximab and panitumumab is mainly 
      considered to be not cost-effective in patients with mCRC. However, testing for 
      Kirsten ras oncogene (KRAS) mutation prior to the treatment with cetuximab or 
      panitumumab is found to be clearly cost-effective compared to no testing. Future 
      research should focus on the CE of first-line treatment with cetuximab or 
      panitumumab and studies on upcoming agents like regorafenib and aflibercept.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Lange, A
AU  - Lange A
AD  - Leibniz University Hannover, Center for Health Economics Research Hannover 
      (CHERH), Hannover, Germany. Electronic address: al@ivbl.uni-hannover.de.
FAU - Prenzler, A
AU  - Prenzler A
AD  - Leibniz University Hannover, Center for Health Economics Research Hannover 
      (CHERH), Hannover, Germany. Electronic address: ap@ivbl.uni-hannover.de.
FAU - Frank, M
AU  - Frank M
AD  - Leibniz University Hannover, Center for Health Economics Research Hannover 
      (CHERH), Hannover, Germany. Electronic address: mf@ivbl.uni-hannover.de.
FAU - Kirstein, M
AU  - Kirstein M
AD  - Hannover Medical School, Department of Gastroenterology, Hepatology and 
      Endocrinology, Hannover, Germany. Electronic address: 
      Kirstein.Martha@mh-hannover.de.
FAU - Vogel, A
AU  - Vogel A
AD  - Hannover Medical School, Department of Gastroenterology, Hepatology and 
      Endocrinology, Hannover, Germany. Electronic address: Vogel.Arndt@mh-hannover.de.
FAU - von der Schulenburg, J M
AU  - von der Schulenburg JM
AD  - Leibniz University Hannover, Center for Health Economics Research Hannover 
      (CHERH), Hannover, Germany. Electronic address: jms@ivbl.uni-hannover.de.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20130904
PL  - England
TA  - Eur J Cancer
JT  - European journal of cancer (Oxford, England : 1990)
JID - 9005373
RN  - 0 (Antibodies, Monoclonal)
SB  - IM
MH  - Antibodies, Monoclonal/*economics/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*economics/*therapeutic use
MH  - Colorectal Neoplasms/*drug therapy/*economics
MH  - Cost-Benefit Analysis
MH  - Humans
OTO - NOTNLM
OT  - Advanced colorectal cancer
OT  - Bevacizumab
OT  - Cetuximab
OT  - Cost-effectiveness analysis
OT  - Cost-utility analysis
OT  - Health economics
OT  - Metastatic colorectal cancer
OT  - Monoclonal antibody
OT  - Panitumumab
OT  - Targeted therapy
EDAT- 2013/09/10 06:00
MHDA- 2014/05/16 06:00
CRDT- 2013/09/10 06:00
PHST- 2013/05/27 00:00 [received]
PHST- 2013/07/24 00:00 [revised]
PHST- 2013/08/12 00:00 [accepted]
PHST- 2013/09/10 06:00 [entrez]
PHST- 2013/09/10 06:00 [pubmed]
PHST- 2014/05/16 06:00 [medline]
AID - S0959-8049(13)00772-7 [pii]
AID - 10.1016/j.ejca.2013.08.008 [doi]
PST - ppublish
SO  - Eur J Cancer. 2014 Jan;50(1):40-9. doi: 10.1016/j.ejca.2013.08.008. Epub 2013 Sep 
      4.